Search
Monopar Therapeutics Inc
MNPRAdd to Watchlist
88.840USD
-0.540-0.60%
Close 09-24 16:00（ET）
595.23MMarket Cap
LossP/E TTM
After-hours 16:41 (ET)88.800USD-0.300-0.34%
After-hours 16:41 (ET)Monopar Therapeutics Inc (MNPR) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Monopar Therapeutics Inc in the past month.
Buy
2 Strong Buy
11 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
127.615USD+42.78%
MNPR Analyst Recommendation Trends
In the current month, MNPR has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MNPR average Analyst price target in the last month is 127.615.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
3
3
3
3
3
3
11
11
11
11
11
11
10
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
14
14
14
14
13
13
MNPR Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, MNPR EPS is projected to reach -0.869 in FY2026Q3, following reported EPS of -0.622 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.49
-0.84
-0.62
-0.87
-1.16
Actual
-0.61
0.46
-0.62
--
--
Surprise
-23.64%
+155.06%
-0.15%
--
--
FAQs
What is Monopar Therapeutics Inc's price target?
Analysts forecast that Monopar Therapeutics Inc's price target is USD 127.62, with the highest forecast at USD 145.00 and the lowest forecast at USD 100.00.
How have Monopar Therapeutics IncMNPR's recent earnings per share performed?
The market expectation was USD -0.62, while Monopar Therapeutics IncMNPR's earnings per share (EPS) for the previous quarter was USD 0.46. EPS for the next quarter is expected at USD -0.87.
What is the analyst rating for Monopar Therapeutics Inc?
Based on the ratings of Monopar Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.